SCHEMBL21067642

SCHEMBL21067642

C=CCC(C=O)C1CCCC1O

nearest known ligand 0.55

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20877624 0.74 F2 (0.36) F2
SCHEMBL23752578 0.72 F2 (1.00) F2
SCHEMBL1878001 0.71 ALDH1A1 (0.32) F2
SCHEMBL27369711 0.70
SCHEMBL13701168 0.69 F2 (0.42) F2
SCHEMBL16765955 0.68 F2 (0.43) F2
SCHEMBL7063103 0.64 F2 (0.35) F2
SCHEMBL19029406 0.61
SCHEMBL1274061 0.60
SCHEMBL1274063 0.60

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11446398-B2 Regulated biocircuit systems OBSIDIAN THERAPEUTICS, INC. (US) 2022-09-20 US disclosed
US-20210254056-A1 IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS CAMP4 THERAPEUTICS CORPORATION 2021-08-19 US disclosed
US-20190192691-A1 REGULATED BIOCIRCUIT SYSTEMS OBSIDIAN THERAPEUTICS, INC. 2019-06-27 US disclosed